Description

IL-17, also known as CTLA-8, is a T cell-expressed pleiotropic cytokine that exhibits a high degree of homology to a protein encoded by the ORF13 gene of herpes virus Saimiri. IL-17 is produced by Th cells (Th17) that are distinct from the traditional Th1- and Th2-cell subsets. IL-23 plays an important role in triggering IL-17 production. Both recombinant and natural IL-17 have been shown to exist as disulfide linked homodimers. IL-17 exhibits multiple biological activities on a variety of cells including: the induction of IL-6 and IL-8 production in fibroblasts, activation of NF-κB, and costimulation of T cell proliferation. IL-17 is an essential inflammatory mediator in the development of autoimmune diseases. Neutralization of IL-17 with monoclonal antibody is able to ameliorate the disease course.

Formulation

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 650™ excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 650™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Kennedy J, et al. 1996. J. Interferon Cytokine Res. 16:611.
2. Schubert D, et al. 2004. J. Immunol. 172:4503. (ICFC)
3. Infante-Duarte C, et al. 2000. J. Immunol. 165:6107. (ICFC, ELISA Capture)
4. Harrington LE, et al. 2005. Nature Immunol. doi:10.1038/ni1254. (ICFC, ELISA Capture)
5. Nekrasova T, et al. 2005. J. Immunol. 175:2734. (ELISPOT Capture)
6. Yen D, et al. 2006. J. Clin. Invest. 116:1310. (Neut)
7. Ehirchiou D, et al. 2007. J. Exp. Med. 204:1519. (ICFC)
8. Kang SG, et al. 2007. J. Immunol. 179:3724. (ICFC)
9. Smith E, et al. 2008. J. Immunol. 181:1357. (Neut) PubMed
10. Neufert C, et al. 2007. Eur. J. Immunol. 37:1809. PubMed
11. Wang C, et al. 2009. Mucosal Immunol 2:173. (ICFC) PubMed
12. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (ICFC) PubMed
13. Kivisäkk P, et al. 2009. Ann. Neurol. 65:457. PubMed
14. Cooney LA, et al. 2011. J. Immunol. 187:4440. PubMed
15. Ma Y, et al. 2012. PLoS One. 7:e40763. PubMed
16. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed